# Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

> **NCT00649181** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Metolazone Tablets 5 mg
- **DRUG:** Zaroloxyn® Tablets 5 mg

## Key facts

- **NCT ID:** NCT00649181
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649181, "Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00649181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*